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Impaired kidney function is a well-recognized com-
plication following liver transplantation (LT). Studies
of this complication in children have been limited by
small numbers and insensitive outcome measures.
Our aim was to define the prevalence of, and iden-
tify risk factors for, post-LT kidney dysfunction in a
multicenter pediatric cohort using measured glomeru-
lar filtration rate (mGFR). We conducted a cross-
sectional study of 397 patients enrolled in the Stud-
ies in Pediatric Liver Transplantation (SPLIT) registry,
using mGFR < 90 mL/min/1.73 m2 as the primary
outcome measure. Median age at LT was 2.2 years.
Primary diagnoses were biliary atresia (44.6%), ful-
minant liver failure (9.8%), metabolic liver disease
(16.4%), chronic cholestatic liver disease (13.1%), cryp-
togenic cirrhosis (4.3%) and other (11.8%). At a mean
of 5.2 years post-LT, 17.6% of patients had a mGFR <
90 mL/min/1.73 m2. In univariate analysis, factors asso-
ciated with this outcome were transplant center, age at
LT, primary diagnosis, calculated GFR (cGFR) at LT and
12 months post-LT, primary immunosuppression, early
post-LT kidney complications, age at mGFR, height
and weight Z-scores at 12 months post-LT. In multivari-
ate analysis, independent variables associated with a
mGFR <90 mL/min/1.73 m2 were primary immuno-
suppression, age at LT, cGFR at LT and height Z-score
at 12 months post-LT.
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Introduction
Introduction of the calcineurin inhibitors cyclosporine and
tacrolimus revolutionized solid organ transplantation by de-
creasing acute allograft rejection and early graft loss, and
increasing patient and graft survival. However, as long-term
posttransplant survival has improved, adverse effects as-
sociated with the chronic use of these medications have
emerged, among them, the risk of chronic nephrotoxicity,
which leads to kidney dysfunction in almost one-third and
to chronic kidney disease in up to 21% of all solid organ
transplant recipients (1–10). In LT recipients in particular,
the risk of chronic kidney disease in adults is up to 18% by
13 years posttransplant (11). The morbidity and mortality
of this complication in pediatric transplant recipients are
potentially greater than those described in adults, as chil-
dren have a longer life span following transplantation with
greater cumulative exposure to the calcineurin inhibitors
and other nephrotoxic drugs (12–14). In addition, the im-
pact on kidney function of physiologic changes associated
with pubertal growth and development in this population is
unknown. These changes may accelerate the progression
of calcineurin inhibitor induced nephrotoxicity as has been
noted in other chronic nephropathies (15–18).
One of the goals of long-term posttransplant management
is to prevent or delay the onset of late complications, such
as chronic kidney dysfunction. In order to accomplish this
goal, we must identify those at risk, define contributing
factors, and develop strategies for intervention. A thorough
examination of the clinical and biochemical risk factors, and
the impact of proposed interventions in pediatric transplant
patients has been hampered by the limitations and biases
associated with small populations, single centers, and vari-
able and insensitive outcome measures. This has resulted
in conflicting reports regarding prevalence, risk factors, tim-




Table 1: Method of measured GFR for each study center
Center Radionuclide Sampling and calculation
A Single injection DTPA Sampling at 2, 2.5, 3 and 3.5 h, single compartment model
B Single injection DTPA Sampling at 2 h, external skull clearance
C Single injection DTPA Sampling at 2, 3 and 4 h, 2 compartment model
D Single injection DTPA Sampling at 1.5 and 2.5 h
E Single injection Plasma and urine sampling at 1 and 2 h
(subcutaneous) Iothalamate
F Single injection DTPA < 50 kg—sampling at 1,2 and 3 h > 50 kg—sampling at 2,3
and 4 h, single compartment model
G Single injection DTPA Sampling at 0, 1.5, 2, 2.5 and 3 h
H Single injection Iothalamate Sampling at 5, 10, 30 min, 1, 2, 3 and 4 h, 2 compartment model
I Single injection DTPA Sampling at 2, 3 and 4 h, single compartment model
In this multicenter study of pediatric LT recipients, we
have employed the Studies in Pediatric Liver Transplan-
tation (SPLIT) database to define the prevalence of post-LT
kidney impairment using the gold standard for kidney func-
tional assessment, mGFR (29). In addition, we have used
this robust clinical database to identify variables associ-
ated with the development of kidney dysfunction in this
population. The work done here will serve as a foundation
for clinical trials and/or comparative effectiveness analyses
focusing on strategies to optimize kidney function in future
and current post-LT patients.
Patients and Methods
Patients
This cross-sectional study is a component of the larger SPLIT prospective
database, which has been approved by the Institutional Review Boards of all
involved institutions, and inclusion in which requires written informed con-
sent by the parent/guardian. Clinical data submitted to SPLIT are collected
prospectively from the time of transplant listing, with individual reports de-
signed to capture key events such as transplant, rejection, infection and
other discrete posttransplant complications.
Patient inclusion criteria for this analysis were enrollment in SPLIT, time
since LT ≥ 300 days, and mGFR completed as part of standard posttrans-
plant clinical care. Exclusion criteria included previous LT predating SPLIT en-
rollment, receipt of nonhepatic solid organ transplant, only available mGFR
obtained < 300 days post-LT. Data were retrieved from the SPLIT database
and, when possible, missing data were captured by targeted chart review
at individual centers.
GFR and Z-score measurements
All mGFRs are expressed as mL/min/1.73 m2 and were completed via ra-
dionuclide clearance technique in nonacutely ill posttransplant outpatients
as a component of standard clinical care. The specific methods employed
at each of the centers are presented in Table 1. The primary outcome mea-
sure, kidney dysfunction, was defined as a mGFR < 90 mL/min/1.73 m2
corresponding to stage 2 or greater chronic kidney disease as defined by
the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI) (30). Calculated GFRs were obtained using the Schwartz formula
(31). Standardized weight and height Z-scores were calculated by reference
to age-specific and sex-specific charts for the normal population, as provided
by the Centers for Disease Control (http://www.cdc.gov/growthcharts/)
(32).
Statistical analysis
In the univariate analysis, independent variables including demographic
characteristics and clinical characteristics collected at LT, 30 days post-
LT, 12 months post-LT and at mGFR follow-up were compared between
patients with a mGFR < 90 mL/min/1.73 m2 and those with a mGFR ≥
90 mL/min/1.73 m2. The Pearson chi-square test was used to compare
categorical variables and the Wilcoxon rank sum test was used for continu-
ous variables. Independent variables with a p-value < 0.10 in the univariate
analysis were included in the multivariable logistic regression model. Model
reduction was performed using the backward elimination method, and fac-
tors remaining significant at a p-value ≤ 0.05 were maintained in the final
model. As a secondary analysis, a generalized linear mixed-effects model
was created to control for possible center effect. To investigate the possi-
bility of selection bias at the participating centers, basic demographic and
clinical variables were compared between our study population (N = 397)
and the population of mGFR-eligible patients seen at participating centers
over the same time period and meeting center-specific criteria for mGFR
screening, but who did not have a mGFR completed (N = 198). All statistical
analyses were performed using the SAS System for Windows version 8.02
or higher (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
We identified 397 patients from nine North American trans-
plant centers who met inclusion criteria, and who had
a mGFR completed between July 2003 and December
2008. These patients comprise the study group. When
compared to the mGFR-eligible SPLIT cohort (N = 198), the
study population included more males (50.1% vs. 39.4%,
p = 0.013), more Caucasian patients (72.8% vs. 58.6%,
p = 0.022), and more patients transplanted before 2000
(32% vs. 21.2%, p = 0.02). There were no differences
between the study cohort and the mGFR eligible cohort
with regard to distribution of age at LT, primary diagnosis,
calculated PELD score at LT, calculated GFR at LT, or base
immunosuppression at 30 days and 12 months post-LT.
The distribution of mGFRs by transplant center is shown
in Figure 1. At a mean of 5.2 years post-LT, 17.6% of pa-
tients had a mGFR < 90 mL/min/1.73 m2. Based on the
National Kidney Foundation Classification of Chronic Kid-
ney Disease (CKD), 14.6% have stage 2 CKD (GFR 60–89),
2.5% have stage 3 CKD (GFR 30–59) and 0.5% have stage
4–5 CKD (GFR < 30) (Figure 2).
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Figure 1: Distribution of mGFRs by transplant center (with means).
Forty-four patients (11.1%) had a calculated GFR
<90 mL/min/1.73 m2 at the time of LT. Of these, the
majority (70.5%) had an improvement in GFR with time;
only 29.5% (N = 13) had evidence of kidney dysfunc-
tion at follow-up. Of the patients with a calculated GFR
≥ 90 mL/min/1.73 m2 at LT, 15.6% (N = 52) had kidney
dysfunction at follow-up (Figure 3).
Figure 4 presents the mGFR along with the cGFR from the
same visit, and illustrates the relationship between these
two measures of kidney function in our population.
Univariate analysis
Twelve month post-LT characteristics were included as


























Figure 2: Distribution of mGFRs by CKD stage (with means).
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cGFR < 90 ml/min/1.73m2 at LT cGFR  90 ml/min/1.73m2 at LT 
44 patients 
13 (29.5%) with  
mGFR < 90  
at follow-up
31 (70.5%) with 
mGFR  90 
at follow-up
333 patients 
52 (15.6%) with 
mGFR < 90 
at follow-up
 281 (84.4%) with 
mGFR  90 
at follow-up
Figure 3: mGFR at post-LT follow-
up by cGFR at LT.
reason, the 70 patients whose mGFR was completed at
their 12-month follow-up visit, or for whom 12-month in-
formation was unavailable, were excluded from analysis,
bringing the sample size to 327 (Table 2).
Variables associated with a mGFR < 90 mL/min/1.73 m2
included transplant center, older age at LT, primary diagno-
sis, cGFR < 90 mL/min/1.73 m2 at LT and at 12 months
post-LT, cyclosporine immunosuppression at 30 days and
12 months post-LT, kidney complications in the first 30
days post-LT, lower height and weight Z-score at 12 months
post-LT and age ≥ 13 years at follow-up. Other indepen-
dent variables, including race, sex and time since LT, did
not differ significantly between groups.
Multivariate analysis
As we were interested in identifying early factors associ-
ated with long-term posttransplant kidney dysfunction, the
multivariate analysis did not include clinical information col-
lected at the time of the mGFR visit, with the exception
of age at follow-up (<13 years, ≥ 13 years), which was
used as a surrogate marker of pubertal status. All other
variables with a p-value ≤ 0.10 were included in the logis-
tic regression model. Patients with incomplete data sets
were excluded, leaving 289 patients.
In the multivariate analysis, four factors were identi-
fied as being independently associated with a mGFR <
90 mL/min/1.73 m2 at last follow-up (Table 3): transplant
Mean SE Median
mGFR 116 1.6 113
cGFR 148 2.1 145
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Figure 4: mGFR and cGFR at follow-up.
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Table 2: Univariate analysis comparing patients with and without post-LT renal dysfunction (N = 327)
Variable mGFR < 90 (n = 54) mGFR ≥ 90 (n = 273) p-Value
16.5% 83.5%
Transplant center (%) 0.0044
Center A 12 88
Center B 13.5 86.5
Center C 39.1 60.9
Center D 16 84
Center H 8.3 91.7
Others (centers E, F, G, I) 28.8 73.2









Primary diagnosis (%) 0.0228
Biliary atresia 10.5 89.5
Chronic cholestatic liver disease 31.7 68.3
Fulminant liver failure 13.5 86.5 77.1
Metabolic liver disease 22.9 85.7
Cryptogenic cirrhosis 14.3 79.4
Other 20.6
Patient status at LT (%) 0.6269
ICU 20.7 79.3
Hospitalized, not in ICU 14.8 85.2
Not hospitalized 15.9 84.1
cGFR at LT (%) 0.0131
<90 mL/min/1.73 m2 29.3 70.7
≥90 mL/min/1.73 m2 14 86
Calculated PELD score at LT (%) 0.3267
< 0 19 81
0–10 15.7 84.3
10–20 8.3 91.7
≥ 20 16.5 83.5
Height Z-score at LT (%) 0.1005
Above 2 SD (normal) 13.9 86.1
Below 2 SD (impaired) 21.2 78.8
Weight Z-score at LT (%) 0.6808
Above 2 SD (normal) 15.7 84.3
Below 2 SD (impaired) 17.6 82.4
Year of 1st LT (%) 0.4699
1995–2000 18.4 81.6
2001–2006 15.3 84.7
Immunosuppression at day 30 post-LT (%) 0.0182
Cyclosporine 26.2 73.8
Tacrolimus 13.8 86.2
Kidney complications in first 30 days post-LT (%) 41.2 58.8 0.0049
No kidney complications (%) 15.2 84.8
Vascular complications in first 30 days post-LT (%) 25.5 74.5 0.0602
No vascular complications (%) 14.9 85.1
Hepatic artery thrombosis in first 30 days post-LT (%) 29.4 70.6 0.1413
No hepatic artery thrombosis (%) 15.8 84.2
Retransplanted in first 30 days post-LT (%) 25 75 0.4199
Not retransplanted in first 30 days (%) 16.2 83.8
Days hospitalized in first 30 days post-LT 0.1444
< 30 days 14.6 85.4
30 days 21.4 78.6
Continued
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Table 2: Continued
Variable mGFR < 90 (n = 54) mGFR ≥ 90 (n = 273) p-Value
cGFR at 12 months post-LT (%) 0.0041
<90 mL/min/1.73 m2 33.3 66.7
≥90 mL/min/1.73 m2 13.9 86.1
Immuno-suppression at 12 months post-LT (%) 0.0071
Cyclosporine 29.4 70.6
Tacrolimus 14.1 85.9





Height Z-score at 12 months post-LT (%) 0.0004
Above 2 SD (normal) 12 88
Below 2 SD (impaired) 29.3 70.7
Weight Z-score at 12 months post-LT (%) 0.0236
Above 2 SD (normal) 14.1 85.9
Below 2 SD (impaired) 27.1 72.9
Age at mGFR follow-up (%) <0.0001
<13 years 11.4 88.6
13+ years 31.7 68.3
Number of transplants (%) 0.2060
1 15.7 84.3
2 or 3 25 75
Time since transplant—years (mean ± SD) 6.26 (± 3.41) 5.93 (± 2.75) 0.7828
center, older age at LT, cGFR < 90 mL/min/1.73 m2 at LT,
and height Z-score more than 2 standard deviations below
normal at 12 months post-LT.
Since transplant center and primary immunosuppression
were highly correlated (uncertainty coefficient of 0.41),
a secondary model was developed to control for center-
specific effects. This model assumes that each center has
a random effect that reflects the possibility of different
baseline risks for patients at different centers. In this model
(Table 4) age at LT, cGFR at LT and height Z-score at 12
months post-LT remain significant, but immunosuppres-
sion at 12 months post-LT emerges as a factor indepen-
dently associated with mGFR.
Discussion
In this multicenter, cross-sectional study, we found that
17.6% of patients ≥ 1 year post-LT had a mGFR <
90 mL/min/1.73 m2, corresponding to stage 2 or higher
chronic kidney disease. Risk for kidney dysfunction was
directly associated with age at transplant and with a
cGFR < 90 mL/min/1.73 m2 at LT, both of which have
been described previously, primarily in adult populations
(1,10,11,33–35).
By virtue of the cross-sectional design of our study, it was
impossible to define the occurrence of kidney dysfunction
over time; instead we have only a snapshot of this compli-
cation in our population. In addition, since we relied on a
single measure of GFR to classify each patient, it is pos-
sible that patients may have been misclassified. Although
measured GFR is considered the ‘gold-standard’ for as-
sessment of kidney function, assay variability and physi-
ologic variability may affect the reproducibility of a single
measurement. Given that our study population were stable
outpatients undergoing routine, highly protocolized screen-
ing, physiologic variability was likely minimal and, as there
Table 3: Factors associated with post-LT renal dysfunction by logistic regression modeling (n = 289)
Variable Comparison group Reference group Odds ratio 95% CI p-Value
Transplant center B 1.59 0.49–5.23 0.4433
C A 7.58 2.34–24.55 0.0007
D 2.61 0.60–11.31 0.2007
H 1.00 0.26–3.93 0.9959
Other (E, F, G, I) 3.58 1.35–9.54 0.0106
Overall 0.0083
Age at LT continuous 1.24 1.14–1.35 <0.0001
cGFR at LT <90 mL/min/1.73 m2 ≥ 90 mL/min/1.73 m2 3.61 1.40–9.31 0.0080
Height Z-score at 12 months post-LT Below 2 SD (impaired) Above 2 SD (normal) 3.98 1.82–8.70 0.0005
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Table 4: Factors associated with post-LT renal dysfunction by mixed effects modeling with center included as a random effect (n = 289)
Variable Comparison group Reference group Odds ratio 95% CI p-Value
Immunosuppression at 12 months post-LT Cyclosporine Tacrolimus 2.85 1.15 to 7.06 0.0238
Age at LT continuous 1.23 1.14 to 1.35 <0.0001
cGFR at LT <90 mL/min/1.73 m2 ≥ 90 mL/min/1.73 m2 3.57 1.39 to 9.11 0.0080
Height Z-score at 12 months post-LT Below 2 SD (impaired) Above 2 SD (normal) 3.85 1.79 to 8.27 0.0006
is no reason to suspect a systematic bias in the assays
employed, variability on this level is likely to have been
random.
Similar to our results, Arora-Gupta et al. found that younger
age at LT was associated with better long-term kidney func-
tion in pediatric patients (20). In their population, children
less than 1 year of age at the time of LT experienced the
same early decrease in kidney function as did older chil-
dren, but had a greater subsequent and sustained improve-
ment in cGFR (20). The protective effect of younger age
may be related to increased plasticity and/or regenerative
potential of the kidney. There is evidence to support this
type of age-dependent risk for kidney ischemia/reperfusion
injury, in which younger animals are more resistant and re-
cover more rapidly following an ischemic insult (36,37).
In addition, ontogenic differences in calcineurin inhibitor
absorption and metabolism may contribute to different
patterns of calcineurin inhibitor exposure in younger pa-
tients (38). While developmental differences in hepatic
cytochrome p450 activity may not be relevant in a liver
transplant population, there is emerging evidence of an
age-dependent effect of genetic polymorphisms in the
pathway of calcineurin inhibitor absorption on the oral
bioavailability, and thus systemic exposure, of these drugs
(39,40). This may explain the need for TID rather than BID
dosing of cyclosporine that has been described in young
pediatric liver and kidney transplant recipients (25,41,42).
Both pretransplant serum creatinine and cGFR have been
identified as risk factors for later kidney dysfunction in
adult populations. Ojo et al. found that pretransplant cGFR
was inversely related to the relative risk of posttransplant
chronic kidney disease, with even a mild decrease in cGFR
(60–89 mL/min/1.73 m2) associated with a relative risk of
chronic kidney disease of 1.54 (10). Pawarode et al. identi-
fied pretransplant serum creatinine as a risk for posttrans-
plant kidney dysfunction, defined as a decrease in median
GFR more than 30 mL/min/1.73 m2 sustained for at least
6 months (33). Ours is the first study to find this associa-
tion in pediatric LT recipients and, like the Ojo study, our
data indicate that even a mild decrease in pretransplant
cGFR is associated with an increased odds of posttrans-
plant kidney dysfunction. It is important to note that the
majority of patients with a cGFR < 90 mL/min/1.73 m2
at LT and a mGFR > 90 mL/min/1.73 m2 at follow-up (24
of 31) were less than 2 years of age at the time of LT. A
GFR < 90 mL/min/1.73 m2 is normal in this age range, and
the subsequent increase in GFR likely represents normal
age-related physiologic changes. In addition, although 80%
of the patients with kidney dysfunction at follow-up had a
normal cGFR at the time of LT, the propensity of cGFR to
overestimate kidney function (Figure 4) makes it impossi-
ble to define these patients as true ‘de novo’ posttransplant
kidney dysfunction. Therefore, while cGFR at the time of
LT is a powerful risk factor in our analysis, its sensitivity and
specificity at predicting later kidney function in a pediatric
liver transplant population is poor.
This study also found a significant association between
height Z-score at 12 months posttransplant and later kid-
ney dysfunction. In this setting, height Z-score might serve
as an early marker for more severe kidney dysfunction with
secondary growth failure. However, there was no correla-
tion between height Z-score and cGFR at 12 months post-
LT. In addition, a recent analysis by Alonso et al. of linear
growth patterns post-LT using the SPLIT database found
no independent relationship between cGFR at 12 months
post-LT and height Z-score at 24 months post-LT (43). Al-
ternatively, height may serve as a marker for a particular
diagnosis. In our population height Z-score correlated with
primary diagnosis, with the lowest height Z-score at 12
months in the group of patients with ‘other cholestatic’
disorders (data not shown). Thus, low height Z-score may
be a surrogate marker for a particular type of pediatric
cholestatic disorder associated with an increased risk of
posttransplant kidney dysfunction. Alagille syndrome in
particular emerges as a likely candidate due to the asso-
ciation of the syndrome with both growth retardation and
structural and/or functional kidney disease (44). In an at-
tempt to clarify the relationship between kidney function
and diagnosis, we re-analyzed the data stratifying diagno-
sis by known risk of primary kidney involvement (high risk
group: Alagille syndrome, alpha-1-antitrypsin deficiency,
Wilson’s disease, glycogen storage disease, tyrosinemia
and congenital hepatic fibrosis), as did Harambat et al. in
their 2008 paper (28). Interestingly, using this classifica-
tion primary diagnosis was not significant in the univari-
ate analysis (p-value 0.2888). Given the small number of
patients with Alagille syndrome in the cohort (n = 14) it
was not possible to include it as an individual diagnostic
category.
The emergence of transplant center as an independent
factor in the multivariate analysis is intriguing, as a cen-
ter effect has not previously been described in studies
focusing on post-LT outcomes. In this analysis, center ef-
fect was associated with posttransplant kidney function

















0 1 2 3 4 5 6 7 8 9 10 11 12 13 Figure 5: Distribution of mGFR
at follow-up by time since trans-
plant.
independent of other factors considered; however, when
a random mixed effects model was employed to control
for center effect, primary immunosuppression emerges
as an independent risk factor. While an increased risk
of kidney dysfunction with cyclosporine has frequently
been hypothesized, a true difference between cyclosporine
and tacrolimus may be missed in single center studies,
in which the majority of patients receive the same cal-
cineurin inhibitor based on center standard. In addition,
center standards tend to change over time, such that use
of cyclosporine immunosuppression frequently correlates
with transplant era, further complicating any relationship
between immunosuppressive agent and clinical outcome
(22,25,28). Our results are in keeping with the multicenter
study by Ojo and colleagues, in which cyclosporine im-
munosuppression was found to be a risk factor for chronic
kidney disease in LT patients specifically (10). Although the
use of cyclosporine continues to decrease in both pediatric
and adult LT programs, with <10% of patients transplanted
in 2006 receiving cyclosporine as primary immunosuppres-
sion, this is an important factor in that it confers significant
risk and is easily modifiable (45,46).
The ability to discern differences in kidney risk between cy-
closporine and tacrolimus is further confounded by the re-
lationship between immunosuppression regimen, kidney
function and time since transplant, such that time since
transplant correlates with both cyclosporine use and kid-
ney function. A major finding of this work is the lack of
significance of time since transplant (Figure 5), at least
within the follow-up period included in this study (up to 11
years posttransplant).
There are multiple reasons why the baseline risk for kidney
dysfunction, and the impact of additional factors, might dif-
fer across transplant centers. Firstly, patient selection bias
might contribute to a perceived center effect. Although
all involved centers were obtaining mGFRs routinely as
a screening test across their pediatric LT population, the
percentage of eligible patients tested at each center was
variable, ranging from 42 to 92%. The reasons for this
are unclear, although percent enrollment did not correlate
with either center volume or incidence of kidney dysfunc-
tion (data not shown). Furthermore, there were discernable
differences between those patients who had GFRs mea-
sured and those who did not (sex, race, transplant era),
indicating a potential selection bias at one or more centers.
Other potential components of center effect include vari-
ables examined in our study (primary diagnosis, time since
transplant, etc.) but whose significance may have been lost
as a consequence of study design. In our focus on identi-
fying factors associated with kidney function for a hetero-
geneous population of pediatric LT recipients, interactions
among demographic and clinical risk factors that vary from
center to center might be undetectable in the large cohort,
a limitation of the reductionist multivariate analysis. This
is supported by previous reports on post-LT kidney dys-
function from three of the SPLIT centers involved in the
current study (22,23,25). While there was some overlap
in findings, several risk factors identified in each of these
single-center analyses were different compared not only to
one another, but also to the current analysis. This is likely
related, in part, to differences in the overall patient popu-
lations between centers. Unfortunately, given the modest
number of patients contributed by most of the centers in-
volved in the current study, an in-depth analysis of potential
differences in patient populations was not feasible.
Center effect might also include important variables which
we were unable to capture in this analysis. Center-specific
practices, such as use of antihypertensive agents and tar-
get immunosuppression ranges, were beyond the scope of
this study, as were quantitative measures of immunosup-
pression exposure for individual patients. Similarly, since
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mGFRs were included from patients at variable times post-
LT, it is possible that immunosuppression was altered in
response to earlier GFR measurements leading to sub-
sequent improvement in kidney function. The use of de-
creased calcineurin inhibitor dosing in combination with
mycophenolate mofetil is one of several effective kidney-
sparing strategies commonly used in clinical practice but
not captured in this data set (47–50). These potential dif-
ferences among center populations and practices leave
the opportunity for comparative effectiveness studies to
identify best clinical strategies for specific subgroups of
patients.
In spite of these limitations, the availability of rich clinical
data, prospectively captured in the multicenter SPLIT con-
sortia database, allowed us the opportunity to include a
large number of variables that would have been difficult to
capture, and potentially unreliable, within the confines of
a retrospective analysis. This allowed us to identify a set
of risk factors applicable across all participating centers,
and likely applicable across the pediatric LT population as
a whole. Another strength of this study is the use of mea-
sured rather than calculated GFR to assess kidney func-
tion; ours is the first multicenter study in either adults or
children to employ this measure. Accurate and easy as-
sessment of kidney function remains a challenge in pedi-
atric patients with end-stage liver disease and following LT
(29). Although radionuclide GFR provides the most accu-
rate measure of kidney function available clinically, these
procedures are expensive, time consuming, require spe-
cialized training and may not be readily available for smaller
children in predominantly adult institutions. More reliable,
less invasive estimations such as cystatin C-based equa-
tions may offer hope to the bedside clinician. Cystatin C
is a widely expressed protein, the serum level of which
is not affected by height, sex or body composition. While
the data in pediatric transplant recipients are limited to a
single study, cystatin C seems to be a better marker for
assessing kidney dysfunction than serum creatinine and,
if validated in a larger pediatric liver transplant population,
may be an ideal substitute for radionuclide GFRs (51). Un-
til that time, mGFR remains the most appropriate kidney
outcome to assess in the context of a clinical study. For
centers in which mGFR is not routinely employed for pop-
ulation screening, the findings of this study may help direct
targeted testing of high risk patients.
Improvements in patient and graft survival following pe-
diatric LT have left us with a different challenge: main-
taining allograft function while minimizing the long-term
immune and nonimmune complications related to im-
munosuppressive therapy. Kidney dysfunction and the po-
tential for end-stage kidney disease are significant risks for
young transplant patients. This study finds a number of
common factors (immunosuppressive agent, age at trans-
plant, cGFR at transplant, growth failure) associated with
posttransplant kidney dysfunction, and paves the way for
a spectrum of future investigations targeted toward im-
proving care standards and addressing gaps in knowledge
regarding this complication. These results can be used to
risk-stratify patients prior to the onset of kidney dysfunc-
tion, and to test novel interventional therapies in high-risk
groups. This study also identifies the presence of center-
specific risk factors for posttransplant kidney dysfunction.
Further elucidation of the components of this center effect
will require ongoing collaboration among pediatric trans-
plant centers and comparative effectiveness research to
identify and share the best strategies for preventing kid-
ney compromise following pediatric LT.
The authors of this manuscript have no conflicts of inter-
est to disclose as described by the American Journal of
Transplantation.
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